Health Care & Life Sciences » Pharmaceuticals | Mitsubishi Tanabe Pharma Corp.

Mitsubishi Tanabe Pharma Corp. | Income Statement

Fiscal year is April-March. All values JPY Millions.
2014
2015
2016
2017
2018
2019
Sales/Revenue
412,675
415,124
425,764
423,977
433,855
424,767
Cost of Goods Sold (COGS) incl. D&A
181,500
182,174
157,275
165,925
172,201
183,580
Gross Income
231,175
232,950
268,489
258,052
261,654
241,187
SG&A Expense
172,090
165,796
160,957
163,085
182,087
185,258
EBIT
59,119
67,133
-
94,967
79,567
55,929
Unusual Expense
7,175
18,558
26,744
722
8,381
5,780
Non Operating Income/Expense
4,115
12,716
837
830
7,256
21
Interest Expense
90
223
202
181
177
164
Pretax Income
72,441
62,677
83,224
96,035
78,764
50,439
Income Tax
27,032
25,389
26,221
27,137
24,772
18,223
Equity in Affiliates
-
-
31
24
-
-
Consolidated Net Income
45,409
37,288
57,034
68,922
53,992
32,216
Net Income
45,393
39,502
59,306
71,263
57,963
37,372
Net Income After Extraordinaries
45,393
39,502
59,306
71,263
57,963
37,372
Net Income Available to Common
45,393
39,502
59,306
71,263
57,963
37,372
EPS (Basic)
80.92
70.41
105.72
127.03
103.35
66.64
Basic Shares Outstanding
561
561
561
561
561
561
EPS (Diluted)
80.92
70.41
105.72
127.03
103.35
66.64
Diluted Shares Outstanding
561
561
561
561
561
561
EBITDA
78,878
87,078
117,868
105,421
91,102
67,458
Other Operating Expense
34
21
-
-
-
-
Non-Operating Interest Income
1,527
1,577
1,801
1,141
476
555
Minority Interest Expense
16
2,214
2,272
2,341
3,971
5,156
Equity in Affiliates (Pretax)
595
32
-
-
23
80

About Mitsubishi Tanabe Pharma

View Profile
Address
3-2-10 Dosho-machi
Osaka Osaka 541
Japan
Employees -
Website http://www.mt-pharma.co.jp
Updated 07/08/2019
Mitsubishi Tanabe Pharma Corp. engages in the research, development, manufacture, and sale of pharmaceutical products. Its products include Remicade, Ceredist, Talion, Kremezin, Maintate, Simponi, Lexapro, Tenelia, Tetrabik, and Imusera. The company operates through Pharmaceuticals segment.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.